The 14th edition of the Lifesciences & Healthcare Innovation Forum (LHIF) commenced on 16 April at The Leela Palace, Bengaluru, bringing together thought leaders, technologists, clinicians, policymakers, and investors to explore the theme: “AI Disrupt: Transforming Diagnosis, Discovery & Delivery.”
Organized by MeitY – K-tech Nasscom Centre of Excellence (CoE), LHIF comes at a pivotal time when artificial intelligence (AI) is redefining the healthcare landscape, from early diagnosis to drug discovery, medical device innovation, and digital care delivery.
A range of panel discussions covered critical topics including:
AI for Access to Care
Panelists explored how AI is improving healthcare delivery in underserved regions and enabling early interventions impacting the accessibility of healthcare
GenAI in Pharma
A deep dive into how generative AI is being applied for drug discovery, supply chain optimization, and pharmacovigilance, featuring leaders from GSK, L’Oréal Lifesciences, Sravathi AI, and GAVS.
AI in Medical Devices
Insights from R&D and Engineering heads, Clinicians and AI innovators at Danaher, BPL Medical, Aravind Eye Care Systems, and Remidio on the intersection of AI and hardware innovation.
Investor Perspective
VCs and investment leaders from 314 Capital, Mavin Ventures, Ankur Capital, and Speciale Invest discussed the funding landscape, key challenges, and the promise of healthtech startups.
The forum also featured the finale of HIC#6 (Healthcare Innovation Challenge), recognising standout digital and AI adoption use cases from leading institutions such as HCG and Sankara Nethralaya and Rajiv Gandhi Cancer Institute.
Disruptive innovation showcases were held throughout the day to spotlight emerging startups and their cutting-edge solutions in diagnostics, AI-powered analytics, and medtech.
